Attendees who purchased access to the 2015 Molecular Targets and Cancer Therapeutics webcast were sent login information on November 23.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev next > | last >>
presentations: 1 to 25 of 7225
page: of 289 records per page:
Keynote Address
Understanding and overcoming cancer disparities in the U.S. and abroad
Douglas R. Lowy
National Cancer Institute, Bethesda, Maryland
from 2015 Cancer Health Disparities conference on November 13, 2015 6:30 PM-8:15 PM
Educational Session 1: Immunotherapy 101
Immunity against cancer: How to be enhanced?
Jolanda de Vries
Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Educational Session 1: Immunotherapy 101
Gene-modified T cells as biotherapeutics for cancer
Stephen Gottschalk
Baylor College of Medicine, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Educational Session 1: Immunotherapy 101
Immune checkpoint inhibitors: Opportunities and challenges
Mary L. (Nora) Disis
University of Washington, Seattle, WA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 3:00 PM-4:30 PM
Plenary Session 1: Cellular Immunotherapy
Mutation-driven drug development (targeted agents) vs. immunotherapeutics development
Alexander M Eggermont
Gustave Roussy Cancer Institute, Villejuif, Paris-Sud, France
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Plenary Session 1: Cellular Immunotherapy
CAR therapy for cancer: Emerging insights
Crystal L. Mackall
National Cancer Institute, Bethesda, MD, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Plenary Session 1: Cellular Immunotherapy
TIL therapy in the era of immune checkpoint blockade
John B.A.G. Haanen
Netherlands Cancer Inst., Amsterdam, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Plenary Session 1: Cellular Immunotherapy
Engineering T cells with introduced TCRs to effectively target tumors
Philip D Greenberg
Fred Hutchinson Cancer Res. Ctr. & Univ. of Washington, Seattle, WA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 10:00 AM-12:00 PM
Plenary Session 4: Advances in Targeted Therapy
Targeting driving genomic mutations in breast cancer
José Baselga
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Plenary Session 4: Advances in Targeted Therapy
Title to be announced
Jeffrey A. Engelman
Massachusetts General Hospital, Boston, MA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Plenary Session 4: Advances in Targeted Therapy
Basket studies: Lessons learned and future directions
David Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Plenary Session 4: Advances in Targeted Therapy
Dissecting colorectal cancer in multiple targetable subtypes
Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Plenary Session 4: Advances in Targeted Therapy
The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Howard Burris
Sarah Cannon Research Institute, Nashville, TN, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 8, 2015 8:00 AM-10:00 AM
Educational Session 2: Mutation Profiling / Return of Genetic Data
Introduction
Lee J. Helman
National Cancer Institute, Bethesda, MD, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Educational Session 2: Mutation Profiling / Return of Genetic Data
National-scale cancer sequencing and treatment response data integration in The Netherlands
Edwin Cuppen
University Medical Center Utrecht, Utrecht, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Educational Session 2: Mutation Profiling / Return of Genetic Data
Assigning clinical meaning to genomic data for cancer precision medicine
Nikhil Wagle
Dana-Farber Cancer Institute, Brookline, MA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Educational Session 2: Mutation Profiling / Return of Genetic Data
Delivering of the promise of personalized medicine
Gordon B. Mills
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Educational Session 2: Mutation Profiling / Return of Genetic Data
Returning germline results to cancer patients
Sharon E. Plon
Baylor College of Medicine, Houston, TX, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 5, 2015 4:45 PM-6:15 PM
Opening Session
Updates on engineered T cells as cancer therapies
Carl H. June
Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 8:00 AM-9:35 AM
Opening Session
Impact of gut microbiota in cancer development and therapeutics
Laurence Zitvogel
Gustave Roussy Cancer Center, Villejuif, France
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 8:00 AM-9:35 AM
Spotlight on Proffered Papers: Session 1
Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer
Giulia Siravegna
University of Torino - IRCCS Candiolo, Candiolo, Italy
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
Spotlight on Proffered Papers: Session 1
Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology
Paul A. Clarke
Cancer Research UK Unit, The Institute of Cancer Research, London, United Kingdom
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
Spotlight on Proffered Papers: Session 1
Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance
Ryohei Katayama
Japanese Foundation for Cancer Research, Tokyo, Japan
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 3:30 PM-4:10 PM
Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine
The radiology reading room of the future
Robert J. Gillies
Moffitt Cancer Center & Research Institute, Tampa, FL, United States
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 4:15 PM-6:15 PM
Concurrent Session 1: Radiomics: Imaging in the Context of Drug Development and Personalized Medicine
Incorporating molecular imaging methods in early drug development
E. G. Elisabeth De Vries
Univ. Medical Ctr. Groningen, Groningen, Netherlands
from 2015 Molecular Targets and Cancer Therapeutics conference on November 6, 2015 4:15 PM-6:15 PM
<< first | < prev next > | last >>
presentations: 1 to 25 of 7225
page: of 289 records per page: